Etaracizumab
From Wikipedia, the free encyclopedia
Etaracizumab (also known as etaratuzumab[citation needed], MEDI-522, trade name Abegrin) is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer,[1] ovarian cancer[2] and various other types of cancer.[3] It is manufactured by MedImmune.[1]
[edit] References
- ^ a b Statement On A Nonproprietary Name Adopted By The Usan Council: Etaracizumab
- ^ Landen, CN; Kim, TJ; Lin, YG; Merritt, WM; Kamat, AA; Han, LY; Spannuth, WA; Nick, AM et al (2008). "Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer". Neoplasia (New York, N.Y.) 10 (11): 1259–67. PMC 2570602. PMID 18953435. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2570602.
- ^ Delbaldo, C; Raymond, E; Vera, K; Hammershaimb, L; Kaucic, K; Lozahic, S; Marty, M; Faivre, S (2008). "Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors". Investigational new drugs 26 (1): 35–43. doi:10.1007/s10637-007-9077-0. PMID 17876527.
|
|
|
| Tumor ("-t(u[m])-") |
|
Human ("-tumu-")
|
|
|
|
Mouse ("-tumo-")
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(what is this?) (verify)
